Sigma Healthcare's net profit after tax surged 149% to $4.5 million for FY24.
The company booked a 9.2% decrease in revenue, mainly due to divestment and lower rapid antigen test sales.
EBITDA rose 3.9% to $51.5 million, while EBIT grew 20.4% to $23.2 million. Sigma also reduced net debt by 43% and declared a $0.005 per share dividend.
Sigma strengthened its growth profile by securing the Chemist Warehouse supply contract and entering a merger agreement with Chemist Warehouse.